QINGSONG HEALTH (02661) Controlling shareholder Yang Yin voluntarily committed to extend the lock-up period.
Relaxed and Healthy (02661) announced that the board of directors has been informed by the ultimate controlling shareholder, founder, chairman, executive director, and CEO, Ms. Yang Yin, who is full of confidence in the company's future development. In addition to complying with the provisions of Rule 10.07 of the listing rules, she has voluntarily committed to extending the original lock-up period until January 1, 2027.
QINGSONG HEALTH (02661) announced that the board of directors has been informed by Ms. Yang Yin, the ultimate controlling shareholder, founder, chairman, executive director and CEO, that she is confident in the company's future development. In addition to complying with the provisions of Rule 10.07 of the Listing Rules, she has voluntarily committed to extend the original lock-up period to January 1, 2027.
Before the lock-up period expires, Ms. Yang Yin will not sell or enter into any agreements to sell in any way, nor will she establish any subscription rights, rights, interests or property encumbrances on any shares she owns beneficially in the company, including the 43,038,800 shares held by QingSongChou Holdings Corporation, a company wholly owned by her, and any shares she may acquire after exercising share options granted under the company's share incentive plan, including 4,287,180 shares that may be acquired under the share options granted under the Company's pre-IPO share option plan.
Related Articles

US Stock Market Move | AbbVie, Inc. (ABBV.US) rises 6% to acquire Apogee for $10.9 billion.

US Stock Market Move | Novo Nordisk A/S Sponsored ADR Class B (NVO.US) rose by 6% as Semaglutide's market exclusivity in China is extended.

Weak demand combined with operational pressures: Lucid (LCID.US) announced a 18% reduction in its US workforce and the elimination of the COO position.
US Stock Market Move | AbbVie, Inc. (ABBV.US) rises 6% to acquire Apogee for $10.9 billion.

US Stock Market Move | Novo Nordisk A/S Sponsored ADR Class B (NVO.US) rose by 6% as Semaglutide's market exclusivity in China is extended.

Weak demand combined with operational pressures: Lucid (LCID.US) announced a 18% reduction in its US workforce and the elimination of the COO position.

RECOMMEND





